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Abstract 
Left Ventricular Assist Device (LVAD) therapy use is increasing rapidly in 
advanced heart failure (HF). Little data exists on the application of this therapy in 
patients with advanced HF due to hypertrophic cardiomyopathy (HCM). Altered 
ventricular geometry, thickened septum and reduced LV end-diastolic diameter 
(LVEDD) in HCM may lead to increased suction events, arrhythmias and inflow 
cannula malfunction. 
We hypothesized that patients with end stage HCM benefit from LVAD therapy 
and have a similar rate of complications to those with ischemic or dilated CM. 
Between 2009 and 2014, 5 patients with end stage HCM (HCM and EF <50%), 
were implanted with either a HeartMate II ® (80%) or HVAD® (20%) device, as a 
bridge-to-transplant (BTT) (80%) or destination therapy (DT) (20%). We compared 
baseline characteristics, surgical, and long-term clinical outcomes between these 
patients and those receiving an LVAD for end stage dilated and ischemic CM 
(n=214) during that time frame. The HCM cohort had a smaller LVEDD (5.2 versus 
6.9 cm, p=0.001) and a higher LVEF (28% v 18%, p=0.002). 
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Cardiopulmonary bypass time was similar between the groups (72min vs 69min). 
Post-operative length of stay was also similar at 21 days. Operative mortality for 
HCM patients was 0. All 4 BTT patients survived to transplant. LVAD therapy 
resulted in improved LVEDD (5.2 cm to 3.9 cm), PASP (58.8 mmHg to 30.8 
mmHg), and cardiac index (1.5 to 2.82L/min/m2) in patients with HCM, without an 
increased incidence of postoperative complications. Median duration of LVAD 
support in the HCM group was 14 months and 10 months for the control. 
We conclude that select patients with end stage HCM may benefit from LVAD 
therapy with a similar rate of complications compared to traditional candidates. 
Additional study is warranted to further evaluate durable mechanical support in this 
population. 
Keywords: hypertrophic cardiomyopathy, left ventricular assist device, heart 
failure 
 
 
Introduction 
 
Hypertrophic cardiomyopathy (HCM) is a common genetically inherited 
cardiovascular disease, affecting at least 1 in 500 people world-wide (1). It is 
caused by an autosomal dominant mutation in the genes that encode sarcomere 
proteins or sarcomere-associated proteins (2), leading to left ventricular 
hypertrophy of varying morphologies.  The pathophysiology of HCM is complex 
and consists of multiple interrelated abnormalities, including left ventricular outflow  
obstruction, diastolic dysfunction, mitral regurgitation, arrhythmias, and myocardial 
ischemia (3). The clinical diagnosis is usually made by 2D echocardiogram 
imaging or cardiac MRI and it is based on the presence of a hypertrophied  and 
non-dilated left ventricle in the absence of another cardiac or systemic disease that 
could explain the degree of hypertrophy ( ≥ 15mm wall thickness in an adult or 
equivalent indexed to body surface area in a child)(4).  Most patients with HCM 
have normal systolic ejection fraction throughout the disease process. However, 
some progress into a phase characterized by systolic dysfunction, LV dilatation, 
and wall thinning, often referred to as end-stage or “burned-out” HCM (5).  Dilated-
hypokinetic HCM develops in 5-15% of these patients, resulting in rapid 
progression of heart failure symptoms, arrhythmia and ultimately death, and is the 
single most frequent indication for heart transplantation among patients with HCM 
(4,6,7).  
In recent years, left ventricular assist devices (LVAD) have become a standard 
therapeutic option for patients with advanced heart failure (HF) due to dilated or 
ischemic cardiomyopathy, with trials showing benefit in mortality compared to 
medical therapy (8). Patients with HCM present unique challenges for mechanical 
support with smaller LV cavities and increased wall thickness and thus are not 
represented in these trials.  In this study we report the characteristics, surgical and 
long term outcomes of patients with burned out HCM who received LVAD therapy 
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in our institution compared with those who received LVAD as treatment for dilated 
or ischemic cardiomyopathy.  
Methods 
Between 2010 and 2014, five patients with end stage or burned-out HCM, defined 
as patients with a history of HCM and systolic dysfunction with EF <50%, were 
implanted with either a Heart Mate II ® (Thoratec Corp., Pleasanton, CA) or HVAD® 
(HeartWare Corp., Framingham, MA) device as a bridge to transplant (BTT) or 
destination therapy (DT) in our institution. We compared baseline characteristics, 
surgical and long-term outcomes between these patients and non-HCM patients 
who received an LVAD for end stage dilated and ischemic cardiomyopathy during 
the same time frame (n=214). Baseline demographics, laboratory values, 
echocardiographic and catheterization data, operative and post-operative clinical 
variables were obtained via review of the medical record.  
Statistical Methods 
Patient characteristics were summarized by the mean ± standard deviation for 
continuous variables and by frequency counts (percent) for categorical variables.  
Student’s two sample t-test for independent groups and Fisher’s exact test were 
used to compare between HCM and non-HCM groups for continuous and 
categorical data, respectively.  All non-normal and ordinal variables were 
summarized by the median (1st quartile, 3rd quartile) and compared using Mann-
Whitney U test. 
Comparisons of pre and post LVAD implantation data among HCM patients were 
done using paired t-tests for normally distributed continuous variables or Wilcoxon 
matched-pairs signed-ranks test for non-normal and ordinal variables. 
All analysis conducted in SAS v9.4. (SAS Institute Inc., Cary, NC) 
Results 
Baseline characteristics 
There was no difference in baseline demographic characteristics (age, gender, 
BMI) between the patients who received an LVAD for end stage HCM compared to 
non-HCM patients (Table 1). All HCM patients were experiencing NYHA class III-
IV symptoms and were on positive ionotropic agents pre-operatively (versus only 
14% of the control patients), however none received temporary mechanical 
support.  There was no significant difference in pre-operative hemoglobin, renal 
function tests, liver function tests (LFTs), platelets or INR between the groups 
(table 2). 
We found that the HCM cohort had a significantly smaller LV end diastolic 
diameter than the non-HCM cohort (5.2 vs 6.9cm, p=0.001) and a higher LV EF 
(28% vs 18%, p=0.002) (Table 2).  There were no significant differences in MR or 
TR severity between groups. The HCM cohort had a higher pulmonary artery 
wedge pressure than the control group (32 vs 27mmHg, p=0.006); however RA 
pressure, PA systolic pressure and cardiac index values were not significantly 
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different.  Additionally, there was no between group difference in incidence of pre-
operative arrhythmia (ventricular tachycardia or atrial fibrillation) (Table 1). 
 
Table 1. Baseline Patient characteristics 
 Control (n=241) HCM (n=5) p-value 
 
Age 
 
 
57.19 ± 11.79 
 
56.00 ± 13.00 
 
0.82 
Gender 
            Male 
 
 
195 (81%) 
 
 
4 (80%) 
 
 
1.00 
BMI 
 
29.07 ± 5.85 26.00 ± 3.32 0.24 
History of VT 
Yes 
 
77 (47%) 
 
1 (20%) 
 
0.37 
 
History of A Fib 
Yes 
 
 
113 (47%) 
 
 
4 (80%) 
 
 
0.19 
 
Pre-op vasopressor 
Yes 
 
 
33 (14%) 
 
 
5 (100%) 
 
 
<0.001 
 
Pre-op temporary MCS* 
Yes 
 
 
65 (27%) 
 
 
0 (0%) 
 
 
0.33 
 
LVAD type 
Heartmate II 
 
HVAD 
 
 
208 (86%) 
 
33 (14%) 
 
 
4 (80%) 
 
1 (20%) 
 
0.53 
 
                Table 1: All values reposted as n (%), mean ± SD, or median (25%  
                 percentile, 75% percentile).  
 
                 A fib = atrial fibrillation; BMI = Body mass index; VT = ventricular  
                 tachycardia; 
   
                 *temporary mechanical circulatory support = impella, balloon pump, or  
                  ECMO 
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Table 2: Baseline Laboratory and hemodynamic characteristics 
Pre-VAD Control (n=241) HCM (n=5) p-value 
Hb (g/dL) 10.98 ± 1.73 11.48 ± 1.81 0.52 
BUN (mg/dL) 36 ± 20.46 41.60 ± 9.07 0.55 
Creatinine (mg/dL) 1.58 ± 0.81 1.96 ± 0.64 0.29 
Platelets (k/uL) 199.29 ± 85.2 150.2 ± 50.51 0.20 
Albumin (mg/dL) 3.5 (3.2, 4.0) 3.4 (3.4, 3.7) 0.74 
INR 1.4 (1.3, 1.7) 1.6 (1.4, 2.2) 0.19 
AST (U/L) 40.0 (27.0, 76.0) 48.0 (36.0, 65.0) 0.73 
BNP (pg/dL) 1090.42 ±700.98 1366.60 ± 862.48 0.39 
LVEDD (cm) 6.89 ± 1.16 5.18 ± 0.76 0.001 
LV EF (%) 18.46 ± 6.72 28.00 ± 8.15 0.002 
Severe MR (n, %) 
Yes 
 
51 (22%) 
 
0 (0%) 
 
0.59 
Severe TR  (n, %) 
Yes 
 
17  (7%) 
 
0 (0%) 
 
1.00 
RA pressure (mmHg) 14.68 ± 6.67 14.60 ± 7.06 0.98 
PA systolic  
pressure (mmHg) 
 
57.50 ± 13.27 
 
58.80 ± 11.01 
 
0.83 
PVR (Wood units) 4.03 ± 2.69 4.49 ± 2.04 0.71 
Wedge pressure 
(mmHg) 
27.23 ± 7.78 32.00 ± 2.35 0.006 
Cardiac Index 
(L/min/m2) 
1.84 ± 0.55 1.50 ± 0.22 0.17 
Table 2: All values reported as n (%), mean ± SD, or median (25% percentile, 
75% percentile). Hb = Hemoglobin; LVEDD = Left ventricular end diastolic 
diameter; LVEF = Left ventricular ejection fraction; MR= mitral regurgitation; 
TR=tricuspid regurgitation; RA= right atrium; PVR= pulmonary vascular resistance 
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Operative and post-operative outcomes 
80% (n=4) of the HCM patients received a Heart Mate II ® and 20% an HVAD®. 
This was similar to the control group (85% Heart Mate II ® and 15% HVAD®) (table 
1).  80% of the HCM were implanted as bridge to transplant (BTT), with only one 
implantation as destination therapy (DT). The median post-operative length of stay 
was similar between groups at less than 30 days for both.  Median duration of 
LVAD support was also similar at roughly 14 months for both groups. There was 
no difference in post-operative complications including bleeding, stroke, and 
hemolysis between groups. One-year mortality for the HCM patients was zero 
(Table 3).   
Table 3: Post-VAD Outcomes  
 
Post-VAD Control (n=241) HCM (n=5) p-value 
 
RVAD need (n, %) 
Yes 
 
 
19 (8%) 
 
0 (0%) 
 
1.00 
Peri-op pRBCs 
 
7.0 (4.0, 14.0) 2.0 (0.0, 4.0) 0.007 
LOS* (days) 
 
29 (21.0, 43.0) 21.0 (14.0, 33.0) 0.37 
Time to 
Rehospitalization 
(days) 
 
39 (15.0, 99.0) 
 
28 (24.0, 280.0) 
 
0.35 
 
LOS > 30 days  
Yes 
 
 
106 (44%) 
 
 
1 (20% 
 
 
0.37 
 
Rehospitalization 
(1yr) Yes 
 
 
154 (72%) 
 
 
5 (100%) 
 
 
0.33 
 
 
Hemolysis (1yr) Yes 
 
30 (12%) 
 
0 (0%) 
 
1.00 
 
GI bleed (1yr) Yes 
 
71 (29%) 
 
1 (20%) 
 
1.00 
 
Stroke (1yr) Yes 
 
27 (11%) 
 
0 (0%) 
 
1.00 
 
Death  (1yr) Yes 
 
68 (28%) 
 
0 (0%) 
 
1.00 
 
Implant to death or 
transplant (months) 
 
13.7 (3.8, 25.4) 
 
14 (11.0, 16.0) 
 
0.99 
Table 3: All values reposted as n (%), mean ± SD, or median (25% percentile, 
75% percentile).  
pRBC = packed red blood cells; GI = gastrointestinal, LOS=length of stay 
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In the patients with HCM, LVAD therapy resulted in a significant improvement in 
LV end diastolic diameter (from 5.2 cm to 3.9cm), PASP (from 58.8mmHg to 
30.8mmHg), and cardiac index (from 1.5 to 2.82 L/min/m2) after 3 months of 
support (Table 2).   80% of the HCM patients had a baseline history of atrial 
fibrillation compared to 47% in the control group, and all of them experienced post-
operative atrial fibrillation (Table 4). The only HCM patient with a history of pre-
operative VT experienced post-operative VT.  The HCM cohort received a 
combined average of 2.2 units of RBCs post-operatively (Table 3). None of the 
HCM patients required post-operative temporary mechanical support (Extra 
Corporeal Membrane Oxygenation, Impella, Intraortic Balloon Pump or Right 
Ventricular Assist Device). The HCM patients required between 5 and 7 days of 
inotropic support post-operatively, without echo evidence of post-operative right 
ventricular failure or dysfunction.  
 
Table 4: Pre and post VAD comparisons among HCM patients 
Variable 
Pre 
(N=5) 
Post 
(N=5) P-value 
Cardiac Index (L/min/m2) 1.50 ± 0.22    2.82 ± 0.57    0.005 
RV dysfunction  
(1=mild, 2=moderate) 
1.0 (1.0, 2.0) 0.0 (0.0, 1.0) 0.13 
PA systolic pressure 
(mmHg) 
58.80 ± 11.01   30.80 ± 7.05    <0.001 
LVEDD (cm) 5.18 ± 0.76    3.96 ± 0.49    0.020 
LVESD (cm) 4.23 ± 0.71    3.08 ± 0.77    0.002 
Mitral regurgitation  
(1=mild, 2=moderate) 
1.0 (1.0, 2.0)              0.0 (0.0, 0.0) 0.06 
Table 4: All values reposted as n (%), mean ± SD, or median (25% percentile, 
75% percentile).  RV=right ventricle; PA=pulmonary artery; LVESD=left 
ventricle end systolic dimension 
Overall, there was no increased incidence of post-operative arrhythmias, right 
ventricular dysfunction, dialysis, bleeding or CVA in the HCM cohort. All 4 BTT 
HCM patients were successfully transplanted, with one of them receiving a heart-
kidney transplant.  
Discussion 
In this small case series, LVAD was employed in 5 HCM patients with clinical 
success.  Additionally, all four BTT HCM patients were successfully supported to 
orthotopic heart transplant.  Our report adds to a small body of literature 
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demonstrating that, despite difficulties related to the nature of the disease, LVAD 
can be used successfully in selected HCM patients. 
This is one few, and largest, series to report that LVAD therapy can be used in 
patients with end stage HCM, without added morbidity and mortality. The first 
reported case series included four patients with dilated HCM implanted with axial 
continuous flow devices, and showed LVAD therapy did not result in increased 
morbidity or mortality (9). Another case series with three patients showed that 
patients with HCM benefited from LVAD therapy with centrifugal continuous flow 
devices in the short to medium term (10).  Our findings are in agreement with the 
previous reports and add evidence to support use of this technology when and if 
necessary in this population. 
 Patients with end stage HCM represent a different cohort than those with dilated 
and ischemic cardiomyopathy. As mentioned, the pathophysiology of HCM is 
complex and is characterized by left ventricular outflow obstruction, diastolic 
dysfunction, mitral regurgitation, increased burden of arrhythmias, and myocardial 
ischemia.  The ventricular geometry is also different, with small cavities, thicker 
walls, and redundant mitral valve leaflets, which is a potential technical concern for 
LVAD placement and function. They are at a high risk of sudden death due to 
heart failure and arrhythmias; a risk that increases markedly with increase in 
NYHA class (4). Medical therapy for these patients remains limited due to different 
pathophysiology than those with dilated or ischemic cardiac disease.  Afterload 
reduction and diuresis is often poorly tolerated, resulting in increased outflow 
obstruction, hypotension and renal injury, while ionotropic agents can increase the 
risk of arrhythmias (11). LVAD therapy has been shown to improve outcomes in 
patients with advanced dilated or ischemic cardiomyopathy who are failing 
maximal medical therapy (12, 13). However patients with HCM have not been 
represented in the LVAD trials. There is concern for increased suck down events 
and arrhythmias due to smaller LV cavity size in these patients, as well as RV 
dysfunction post LVAD implantation. 
Progression to end stage dilated-hypokinetic stage occurs in ~10-15% of patients 
with HCM (14). Once LV dilatation is established, the evolution toward severe 
heart failure and death is often rapid, with reported refractoriness to medical 
therapy and more severe symptoms than those with idiopathic dilated CM, despite 
overall better EF (6). Duration from onset of end-stage HCM to death or 
transplantation was reported to be only ~2.7 years in one report by Harris, et al. 
(15). This is consistent with our data, showing that all of the HCM patients were 
experiencing NYHA class IV symptoms requiring ionotropic support prior to LVAD 
implantations, despite a significantly higher EF than the control group. A 
combination of altered ventricular geometry with smaller cavity size, resulting in 
similar or even reduced effective stroke volume despite higher EF, as well as 
severe combined diastolic and systolic dysfunction in HCM likely contribute to this 
discrepancy.   
Cardiac transplantation remains the optimal treatment option for end-stage HCM 
patients. However, the numbers of patients needing transplantation and, as a 
result, the transplant wait times are increasing. Consequently, end-stage HCM 
patients are at risk of progressing to irreversible pulmonary hypertension, 
 
The VAD Journal: https://doi.org/10.13023/VAD.2017.08 Page 9 of 11 
 
The VAD Journal: The journal of mechanical assisted circulation and heart failure 
refractory heart failure and ultimately death without further advanced HF therapy 
options. The use of LVAD therapy has markedly increased over the recent years, 
with overall transplant numbers remaining the same. As a result, the proportion of 
patients transplanted after VAD therapy continues to increase.  In the last year, 
approximately 90% of patients undergoing heart transplant in our center had 
previously received an LVAD.  Given high morbidity and mortality associated with 
end-stage HCM and the scarcity of the ideal therapy, heart transplantation, LVAD 
placement is a reasonable next step. This is the largest case series reporting that 
selected patients with end stage HCM can benefit from LVAD therapy without 
increased morbidity and mortality, similarly to those with dilated and ischemic 
cardiomyopathy.  LVAD therapy appears to be a viable therapy for selected 
patients with end stage hypertrophic cardiomyopathy awaiting cardiac 
transplantation.  
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